A Form 4 filed on August 27, 2026 reports that Scott C. Brun, a director of Forte Biosciences, Inc. (NASDAQ:FBRX), disposed of all his outstanding stock options and restricted stock units on August 27, 2026 in connection with a merger transaction.
Key Highlights
- Reporting person: Scott C. Brun, identified as a Director of Forte Biosciences, Inc.
- All positions disposed: Five derivative security positions, including four stock options and one restricted stock unit grant, were all disposed of on August 27, 2026, with zero remaining beneficial ownership in each.
- Merger consideration: The filing references a Merger Agreement dated July 26, 2026, among Forte Biosciences, argenx BV, and Avena Merger Sub Inc., with a per share merger consideration of $77.00.
- Options canceled for cash: Options with exercise prices below $77.00 were canceled and converted into the right to receive a cash payment equal to the excess of $77.00 over the per share exercise price, multiplied by the number of shares subject to each option.
- Out-of-the-money options canceled for no consideration: Options with exercise prices equal to or greater than the merger consideration were canceled with no consideration payable, according to the filing.
- RSUs converted to cash: 18,353 restricted stock units were canceled and converted into the right to receive a cash payment equal to $77.00 multiplied by the total number of shares subject to the RSUs immediately prior to the effective time of the merger.
Scott C. Brun's Derivative Holdings Canceled in Forte Biosciences Merger with argenx
According to the filing, Scott C. Brun, a director of Forte Biosciences, Inc., reported the disposition of all outstanding derivative securities on August 27, 2026. The transactions were made under transaction code "D" and resulted from the Agreement and Plan of Merger dated July 26, 2026, by and among Forte Biosciences, argenx BV as parent, and Avena Merger Sub Inc., a wholly owned subsidiary of argenx BV, as purchaser. The filing states that Company survived the merger as a wholly owned subsidiary of argenx BV.
Four stock option positions were disposed of. A stock option with an exercise price of $25.00 covering 2,000 shares of common stock, a stock option at $20.00 covering 1,000 shares, and a stock option at $8.60 covering 2,000 shares were each canceled and converted into the right to receive a cash payment based on the $77.00 merger consideration, as described in the filing. A fourth stock option with an exercise price of $7.54 covering 31,000 shares was similarly disposed of. Following each transaction, the filing reports zero derivative securities beneficially owned in each position.
In addition, 18,353 restricted stock units, each representing a contingent right to receive one share of Forte Biosciences common stock, were canceled and converted into the right to receive a lump-sum cash payment equal to the $77.00 merger consideration multiplied by the total number of shares subject to those RSUs immediately prior to the merger's effective time, subject to applicable withholding taxes. All positions reported a post-transaction beneficial ownership of zero. The form was signed by Paul A. Wagner, Ph.D., as Attorney-in-Fact, on August 27, 2026.
What Was Disclosed
Director Scott C. Brun disclosed the cancellation of four stock options and 18,353 restricted stock units in connection with the merger of Forte Biosciences with a subsidiary of argenx BV, resulting in zero remaining beneficial ownership of any reported derivative securities.




Please wait processing your request...